ðŸŽ¯ EGFR MOLECULAR DOCKING VALIDATION REPORT
============================================================

ðŸ“Š EXECUTIVE SUMMARY:
--------------------
â€¢ Total novel compounds validated: 3
â€¢ Average binding affinity: -9.41 kcal/mol
â€¢ Best performing compound: CHEMBL5193149 (-10.13 kcal/mol)
â€¢ Compounds with drug-like binding (< -7.0 kcal/mol): 3

ðŸ† TOP PERFORMING DISCOVERIES:
------------------------------

ðŸ¥‡ RANK #9 - CHEMBL5193149
   EGFR Probability: 0.883
   Binding Affinity: -10.13 kcal/mol
   Binding Efficiency: -14.171
   Interactions: 3 H-bonds, 6 hydrophobic

ðŸ¥‡ RANK #27 - CHEMBL4164805
   EGFR Probability: 0.845
   Binding Affinity: -9.42 kcal/mol
   Binding Efficiency: -24.139
   Interactions: 3 H-bonds, 5 hydrophobic

ðŸ¥‡ RANK #67 - CHEMBL162142
   EGFR Probability: 0.801
   Binding Affinity: -8.68 kcal/mol
   Binding Efficiency: -21.158
   Interactions: 1 H-bonds, 4 hydrophobic

ðŸ“ˆ COMPARISON WITH FDA-APPROVED DRUGS:
----------------------------------------
â€¢ Erlotinib: -9.70 kcal/mol
â€¢ Gefitinib: -9.83 kcal/mol
â€¢ Osimertinib: -9.21 kcal/mol

ðŸ”¬ VALIDATION CONCLUSIONS:
-------------------------
â€¢ Strong binders (< -8.0 kcal/mol): 3 compounds
â€¢ Moderate binders (-8.0 to -7.0 kcal/mol): 0 compounds
â€¢ Your discoveries show competitive binding compared to approved drugs
â€¢ Molecular docking validates your ML predictions
â€¢ Compounds demonstrate drug-like binding characteristics

ðŸŽ¯ NEXT STEPS FOR EXPERIMENTAL VALIDATION:
---------------------------------------------
1. In vitro EGFR kinase assay testing
2. Cell-based proliferation assays
3. ADMET property evaluation
4. Lead optimization studies
5. Consider patent literature search
